Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Pulmonx (NASDAQ:LUNG) issued its earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04, FiscalAI reports. The company had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.72 million. Pulmonx had a negative return on equity of 90.27% and a negative net margin of 55.03%.

Here are the key takeaways from Pulmonx’s conference call:

• Second-quarter revenue was $22.8 million, down 5% year over year. U.S. revenue declined 4% but increased 7% sequentially, while the international decline was attributed to the suspension of China shipments; 12 new U.S. treating centers were added.
• Management reiterated its 2026 revenue guidance of $90 million to $92 million and expects to return to year-over-year growth later this year, potentially exiting 2026 at or near double-digit growth as new sales representatives ramp.
• Cost reductions produced meaningful operating leverage: net loss fell 34% to $10.1 million and adjusted EBITDA loss improved nearly 40% to $5.1 million. Full-year operating expenses are now expected at $109 million to $111 million, with cash burn projected at approximately $23 million.
• Pulmonx renewed its Chinese registration certificate in June and expects to resume distributor shipments in early 2027; excluding China, international revenue grew 9% on a constant-currency basis. Second-quarter gross margin rose to 78%, and full-year guidance was raised to approximately 76%.
• Enrollment in the pivotal CONVERT II trial for AeriSeal is progressing toward completion in 2027. Management views AeriSeal as a potential tool to expand the global addressable market for Zephyr valves by roughly 20%, with earlier commercial availability possible in certain European markets after local enrollment is complete.

Pulmonx Trading Up 0.3%

Pulmonx stock traded up $0.01 during trading hours on Friday, reaching $1.61. The company had a trading volume of 417,043 shares, compared to its average volume of 488,507. The firm has a market cap of $68.21 million, a price-to-earnings ratio of -1.39 and a beta of 0.30. Pulmonx has a 12-month low of $1.13 and a 12-month high of $2.89. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. The company has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.47.

Analyst Ratings Changes

Several research firms have recently issued reports on LUNG. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.50.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP bought a new position in shares of Pulmonx during the fourth quarter valued at about $4,312,000. Vestal Point Capital LP bought a new position in Pulmonx during the 3rd quarter valued at approximately $1,345,000. State Street Corp lifted its holdings in Pulmonx by 3.6% in the 4th quarter. State Street Corp now owns 821,217 shares of the company’s stock worth $1,815,000 after buying an additional 28,813 shares during the period. Bank of America Corp DE grew its position in shares of Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after buying an additional 407,971 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Pulmonx by 39.0% during the fourth quarter. Barclays PLC now owns 472,251 shares of the company’s stock valued at $1,044,000 after buying an additional 132,569 shares during the period. 91.04% of the stock is currently owned by institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.